Small bowel enteropathy associated with olmesartan medoxomil treatment

RDF 

 
Το τεκμήριο παρέχεται από τον φορέα :
Ελληνική Γαστροεντερολογική Εταιρία
Αποθετήριο :
Annals of Gastroenterology
δείτε την καρτέλα τεκμηρίου
μέσα από τον ιστότοπο του αποθετηρίου του φορέα *
κοινοποιήστε το τεκμήριο



Σημασιολογικός εμπλουτισμός/ομογενοποίηση από το EKT

2016 (EL)
Small bowel enteropathy associated with olmesartan medoxomil treatment (EN)

Tsigaridas, Athanasios; Department of Gastroenterology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece
Mantzaris, Gerassimos J.; Department of Gastroenterology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece
Karatzas, Pantelis S.; Department of Gastroenterology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece
Vourlakou, Christina; Department of Pathology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece
Varytimiadis, Lazaros; Department of Gastroenterology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece
Galanopoulos, Michail; Department of Gastroenterology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece
Archavlis, Emmanuel; Department of Gastroenterology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece
Viazis, Nikos; Department of Gastroenterology, “Evaggelismos-Ophthalmiatreion Athinon-Polycliniki”, Athens, Greece

Sprue-like enteropathy associated with treatment with olmesartan medoxomil, an angiotensin II receptor blocker, has been described recently. Herein, we report two patients who developed chronic severe non-bloody diarrhea, weight loss, and muscle wasting after prolonged use of olmesartan. Histologic and immunohistochemical examination of multiple duodenal biopsies revealed severe villous atrophy. Clinical signs ceased upon drug discontinuation. Physicians should be aware of this enteropathy even if olmesartan has been taken for months or years. Whether this adverse event is specific for olmesartan or is a class effect of angiotensin II receptor blockers is currently unknown. To the best of our knowledge, these case reports are the first reported in Greece.Keywords Sprue-like enteropathy, olmesartan, villous atrophyAnn Gastroenterol 2017; 30 (1): 131-133 (EN)

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2016-12-29


Annals of Gastroenterology (EN)

Annals of Gastroenterology; Volume 30, No 1 (2017); 131 (EN)



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.